Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Presenter: Robert Giugliano
Up Next
Presenter: Martin J. Holzmann
More slides +
Presenter: Robin Hofmann
Presenter: Borja Ibanez